Purpose: Parastomal hernia (PSH) is a common complication following stoma formation. The incidence of PSH varies widely due to several factors including differences in diagnostic modality, observer, definition, and classification used for diagnosing PSH. The aim of this systematic review was to evaluate the diagnostic accuracy of the modalities used to identify PSH.
Methods: Embase, MEDLINE, Cochrane, Web of Science, and Google Scholar databases were searched. Studies reporting PSH incidence rates detected by two or more different diagnostic modalities or inter-observer variation on one diagnostic modality were included. Article selection and assessment of study quality were conducted independently by two researchers using Cochrane Collaboration's tool for assessing risk of bias. PROSPERO registration: CRD42018112732.
Results: Twenty-nine studies (n = 2514 patients) were included. Nineteen studies compared CT to clinical examination with relative difference in incidence rates ranging from 0.64 to 3.0 (n = 1369). Overall, 79% of studies found an increase in incidence rate when using CT. Disagreement between CT and clinical examination ranged between 0 and 37.3% with pooled inter-modality agreement Kappa value of 0.64 (95% CI 0.52-0.77). Four studies investigated the diagnostic accuracy of ultrasonography (n = 103). Compared with peroperative diagnosis, CT and ultrasonography both seemed accurate imaging modalities with a sensitivity of 83%.
Conclusion: CT is an accurate diagnostic modality for PSH diagnosis and increases PSH detection rates, as compared with clinical examination. Studies that specially focus on the diagnostic accuracy are needed and should aim to take patient-reported outcomes into account. A detailed description of the diagnostic approach, modality, definition, and involved observers is prerequisite for future PSH research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00384-019-03499-5 | DOI Listing |
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Numerous drugs (including disease-modifying therapies, cognitive enhancers and neuropsychiatric treatments) are being developed for Alzheimer's and related dementias (ADRD). Emerging neuroimaging modalities, and genetic and other biomarkers potentially enhance diagnostic and prognostic accuracy. These advances need to be assessed in real-world studies (RWS).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
Background: Low-middle income countries in Latin America, including Brazil, face a higher prevalence of cognitive decline compared to high-income countries, leading to social-economic and healthcare implications. Several studies have showed an association between reduced physical function and cognitive decline. However, there remains a gap in the understanding of this relationship within the older Brazilian population.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Individuals with Mild Cognitive Impairment (MCI) and dementia are at greater risk for mental health conditions including depression and anxiety than those without cognitive impairments. Non-pharmacological interventions are considered first-line to address these problems, but access to psychotherapy services for these groups remains limited. Adapted evidence-based therapy approaches, including Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) are effective for treating comorbid mental health conditions in populations with cognitive impairments.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Michigan State University, East Lansing, MI, USA.
Background: Mild Cognitive Impairment (MCI) is the prodromal stage of dementia, including Alzheimer's Disease (AD). Early identification and accurate assessment of MCI are critical for clinical trial enrichment as well as the early intervention of AD. Digital makers offered a unique opportunity for ecologically valid and affordable early detection approaches.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Cumulus Neuroscience, Dublin, Ireland.
Background: Current tools for Alzheimer's disease screening and staging used in clinical research (e.g. ACE-3, ADAS-Cog) require substantial face-to-face time with trained professionals, and may be affected by subjectivity, "white coat syndrome" and other biases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!